This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion
study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small
Cell Lung Cancer naïve to checkpoint inhibitor therapy, Non-Small Cell Lung Cancer who have
progressed on checkpoint inhibitor therapy, Small Cell Lung Cancer ( who have progressed on
platinum-based chemotherapy, and thymic carcinoma.